Vaccine
AssigneeSmithKline Biological S.A.
InventorsBrigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Georges Thiry, Vincent Vande Velde
Life of this patent
Estimating the term…
Abstract
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
Claims19
An attenuated human rotavirus population comprising a single variant or substantially a single variant, which variant is defined by a polypeptide sequence of at least one of:
- a VP4 protein comprising at least one of a phenylalanine (Phe) at position 167, a glutamic acid (Glu) at position 263, and an arginine (Arg) at position 268;
- and,
- a VP7 protein comprising at least one of a methionine (Met) at position 202, and an isoleucine (Ile) at position 299.
Dependencies are inferred from the claim text.